

**Nectar Lifesciences UK Limited**  
Annual Report and Unaudited Financial Statements  
For the year ended 31 March 2019

Company Registration No. 07547409 (England and Wales)

# Nectar Lifesciences UK Limited

## Company Information

---

<b>Directors</b>	Dr D Dua Nectar Lifesciences Limited
<b>Company number</b>	07547409
<b>Registered office</b>	Devonshire House 60 Goswell Road London EC1M 7AD
<b>Accountants</b>	Kingston Smith LLP Betchworth House 57-65 Station Road Redhill Surrey RH1 1DL

---

# Nectar Lifesciences UK Limited

## Directors' Report

For the year ended 31 March 2019

---

The directors present their annual report and financial statements for the year ended 31 March 2019.

### Principal activities

The company is dormant and has not traded during the year.


### Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr D Dua  
Nectar Lifesciences Limited

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board



.....  
Dr D Dua

**Director**

Date: 30.04.2019

# Nectar Lifesciences UK Limited

## Balance Sheet

As at 31 March 2019

---

	Notes	2019 £	£	2018 £	£
<b>Current assets</b>					
Debtors	2	1		1	
<b>Net current assets</b>			<u>1</u>		<u>1</u>
<b>Capital and reserves</b>					
Called up share capital	3		<u>1</u>		<u>1</u>

For the financial year ended 31 March 2019 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved by the board of directors and authorised for issue on 30-04-2019 and are signed on its behalf by:

  
.....  
Dr D Dua  
Director

Company Registration No. 07547409

# Nectar Lifesciences UK Limited

## Notes to the Financial Statements

For the year ended 31 March 2019

### 1 Accounting policies

#### Company information

Nectar Lifesciences UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is Devonshire House, 60 Goswell Road, London, EC1M 7AD.

#### 1.1 Accounting convention

The financial statements are prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 1.2 Profit and loss account

The company has not traded during the year or the preceding financial period. During this time the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

#### 1.3 Financial instruments

The company only has financial instruments classified as basic and measured at amortised cost. The company has no financial instruments that are classified as 'other' or financial instruments measured at fair value.

#### 1.4 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

### 2 Debtors

	2019	2018
	£	£
Amounts falling due within one year:		
Amounts due from group undertakings	1	1

### 3 Called up share capital

	2019	2018
	£	£
Ordinary share capital Issued and fully paid 1 ordinary share of £1	1	1

# Nectar Lifesciences UK Limited

Notes to the Financial Statements (Continued)

For the year ended 31 March 2019

---

## 4 Parent company

The parent company is Nectar Lifesciences Limited, a company registered in India, by virtue of its' 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Disst. S.A.S. Nagar (Mohali) Punjab, India.

A handwritten signature in black ink, consisting of several loops and a wavy tail, positioned above a horizontal line.

# Nectar Lifesciences USA LLC

---

Notes to the Financial Statements  
For the year ended December 31, 2018

## 1. Accounting Policies

### 1.1. Accounting Conventions

The financial statements are prepared under the cost convention and in accordance with the financial reporting standard for smaller entities.

## 2. Control

The immediate controlling party is Nectar Lifesciences Limited, a company registered in India, by virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt: S.A.S. Nagar (Mohali) Punjab, India.

## 3. Balance Sheet and Profit and Loss Accounts

Balance Sheet and Profit and Loss Accounts and attached with reports and entries contained there are self explanatory.

## 4. Audit

Nectar Lifesciences US, LLC, being a privately held company, is not required to get its financial statement audited for the financial year ended on December 31, 2018 under any law of the US.

For ~~Nectar Lifesciences~~ USA, LLC

(Saurabh Goyal)  
President

Date: 20-05-2019

# Nectar Lifesciences USA LLC

## Balance Sheet As At 31st December 2018

Particulars	NOTE	FY 2018		FY 2017	
<b><u>EQUITY AND LIABILITIES</u></b>					
<b>Share holders' Fund</b>					
Share Capital		\$51,950.00		\$51,950.00	
Reserves & Surplus	2.1	<u>\$15,927.41</u>	\$67,877.41	<u>(\$12,512.19)</u>	\$39,437.81
<b>Non Current Liabilities</b>					
<b>Current Liabilities</b>					
Trade Payables	2.2	<u>\$1,155,909.04</u>	\$1,155,909.04	<u>\$70,433.98</u>	\$70,433.98
<b>Total</b>			<u><u>\$1,223,786.45</u></u>	<u><u>\$109,871.79</u></u>	
<b><u>ASSETS</u></b>					
<b>Non Current Assets</b>					
<b>Fixed Assets</b>					
<b>Current Assets</b>					
Inventories	2.3	66,430.00		\$0.00	
Trade Receivables	2.4	\$1,059,105.00		\$48,000.00	
Cash & Bank Balances	2.5	<u>\$98,251.45</u>	1,223,786.45	<u>\$61,871.79</u>	\$109,871.79
			<u><u>\$1,223,786.45</u></u>	<u><u>\$109,871.79</u></u>	

For Nectar Lifesciences USA, LLC

(Saurabh Goyal)  
President

Date: 20-05-2019



# Nectar Lifesciences USA LLC

## Statement of Profit and Loss For the Year Ended 31st December 2018

Particulars	NOTE	FY 2018	FY 2017
<b>INCOME</b>			
Revenue From Operations	2.6	\$3,190,769.80	\$317,170.00
Operating Income	2.7	-	780.00
		<u>\$3,190,769.80</u>	<u>\$317,950.00</u>
<b>EXPENDITURE</b>			
Purchase of Stock in Trade		\$3,066,890.00	\$213,120.00
Changes in Inventories of Stock in Trade	2.8	(\$66,430.00)	\$80,740.80
Other Expenses	2.9	\$161,870.20	\$13,702.00
		<u>\$3,162,330.20</u>	<u>\$307,562.80</u>
<b>PROFIT BEFORE TAX</b>		<b>\$28,439.60</b>	<b>\$10,387.20</b>

For Nectar Lifesciences USA, LLC

(Saurabh Goyal)  
President

Date: 20-05-2019

# Nectar Lifesciences USA LLC

Particulars	FY 2018	FY 2017
<b>NOTE - 2.1 "RESERVES &amp; SURPLUS"</b>		
<b>Surplus in Statement of Profit &amp; Loss</b>		
Opening Balance	(\$12,512.19)	(\$22,377.39)
Transferred From Statement of Profit & Loss	\$28,439.60	\$10,387.20
	<u>\$15,927.41</u>	<u>(\$11,990.19)</u>
<b>Appropriations :</b>		
Corporation Business Tax	\$0.00	\$522.00
<b>Total</b>	<u><b>\$15,927.41</b></u>	<u><b>(\$12,512.19)</b></u>
 <b>NOTE - 2.2 "TRADE PAYABLES"</b>		
Nectar Lifesciences Limited India	\$1,147,121.04	\$70,433.98
Seair Global INC	\$8,788.00	-
	<u><b>\$1,155,909.04</b></u>	<u><b>\$70,433.98</b></u>

For Nectar Lifesciences USA, LLC

(Saurabh Goyal)  
President

Date: 20-05-2019

# Nectar Lifesciences USA LLC

Particulars	FY 2018	FY 2017
<b>NOTE - 2.3 "INVENTORIES"</b>		
<b>(As Certified by The Management)</b>		
Finished Goods	\$66,430.00	-
	<b>66,430.00</b>	<b>\$0.00</b>

<b>NOTE - 2.4 "TRADE RECEIVABLES"</b>		
<b>Unsecured</b>		
Considered Good	\$1,059,105.00	\$60,000.00
Considered Doubtful	-	-
	<b>\$1,059,105.00</b>	<b>\$60,000.00</b>
Provision For Doubtful Debts	\$0.00	12,000.00
	<b>\$1,059,105.00</b>	<b>\$48,000.00</b>

<b>NOTE - 2.5 "CASH &amp; BANK BALANCES"</b>		
<b>Balance With Banks</b>		
In Current Accounts	\$98,251.45	\$61,871.79
	<b>\$98,251.45</b>	<b>\$61,871.79</b>

For Nectar Lifesciences USA, LLC

(Saurabh Goyal)  
President

Date: 20-05-2019

# Nectar Lifesciences USA LLC

Particulars	FY 2018	FY 2017
<b>NOTE - 2.6 "REVENUE FROM OPERATIONS"</b>		
Sale from Operations	\$3,190,769.80	\$317,170.00
	<u>\$3,190,769.80</u>	<u>\$317,170.00</u>
 <b>NOTE - 2.7 "OPERATING INCOME"</b>		
Interest on delayed payments	-	780.00
	<u>\$0.00</u>	<u>\$780.00</u>
 <b>NOTE - 2.8 "CHANGE IN STOCK IN TRADE"</b>		
Inventory (At Close)	\$66,430.00	-
Inventory (At Commencement)	-	\$80,740.80
<b>Change</b>	<u>(\$66,430.00)</u>	<u>\$80,740.80</u>
 <b>NOTE - 2.9 "OTHER EXPENSES"</b>		
<b>Administrative &amp; Selling Expenses</b>		
Freight Charges	\$143,129.20	-
Warehousing Charges	-	\$1,147.00
Professional Charges	\$6,525.00	-
Provision for Bad Debts/ Bad Debts Written off	12,000.00	12,000.00
Bank Charges & Commission	\$216.00	555.00
	<u>161,870.20</u>	<u>13,702.00</u>

For Nectar Lifesciences USA, LLC

(Saurabh Goyal)  
President

Date: 20-05-2019